ClinicalTrials.gg
Drug

Ibrutinib clinical trials

Also written Imbruvica, PCI-32765 and CRA-032765.

studies test it
264
open now
21
in phase 3
32
first study started
2009

How each study uses ibrutinib is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ibrutinib studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
13 Nov 2013 · IMBRUVICA · NDA 205552 (FDA, Drugs@FDA)
European Union
21 Oct 2014 · Imbruvica · EMEA/H/C/003791 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ibrutinib
219
BTK Inhibitor PCI-32765
67
Bruton's tyrosine kinase inhibitor PCI-32765
3
Ibrutinib 560 mg
2
BTK inhibitor
2

Brand

Imbruvica
134

Development codes

PCI-32765
107
CRA-032765
65
JNJ-54179060
9

In one entry with another drug

Given together, or one or the other

SNX-5422 plus ibrutinib
2

Studies by the year they started

264 studies that test it; most in 2016 (47)

Studies that test ibrutinib, by start year
YearStudies
20091
20103
20113
201216
201321
201421
201527
201647
201724
201824
201924
202022
20219
20226
20234
20244
20256
20262

Who runs them

Industry 78 · Other 186

Janssen Research & Development, LLC (30) · Pharmacyclics LLC. (28) · M.D. Anderson Cancer Center (23) · National Cancer Institute (NCI) (20) · Mayo Clinic (8) · Memorial Sloan Kettering Cancer Center (8) · Dana-Farber Cancer Institute (6) · Janssen Pharmaceutical K.K. (5)

Often tested with

Tested in the same studies.

Rituximab (37) · Venetoclax (28) · Lenalidomide (19) · Obinutuzumab (19) · Nivolumab (10) · Bortezomib (7) · Prednisone (6) · Dexamethasone (6)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 5 phase 3 studies under way

Ibrutinib is the comparator. A study of two new drugs counts under both.

  • 2Pirtobrutinib · Loxo Oncology, Inc. · next primary completion Oct 2027
  • 1Acalabrutinib · Acerta Pharma BV
  • 1ARQ531 · Merck Sharp & Dohme LLC · next primary completion Sep 2032
  • 1Rocbrutinib · Guangzhou Lupeng Pharmaceutical Company LTD. · next primary completion May 2031
Reaching primary completion within a year · 21, 2 in phase 3

Studies that test ibrutinib, phase 3 first.

Studies

Open first, then newest update. How each study uses ibrutinib is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 264

See all 264 studies that test ibrutinib →

Given beside what is tested · 63 — ibrutinib is usual care or a partner of the new treatment

Showing 20 of 63.

As the comparator · 10 — what is tested is compared with ibrutinib

Codes

What other systems call ibrutinib · ClinicalTrials.gg INT005692

  • MeSH (NLM) C551803ibrutinibConfirmed ClinicalTrials.gov, NLM
  • UNII (FDA) 1X70OSD4VXIBRUTINIBConfirmed FDA, NLM, Wikidata
  • RxNorm 1442981Confirmed FDA, Wikidata
  • Wikidata Q5984881ibrutinibConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C81934IbrutinibOne source FDA
  • DrugBank DB09053One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.